<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-19 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-19</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-19</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <p><strong>Paper ID:</strong> paper-9304962074baf8bcdf4ba0807623f5879efdca06</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/9304962074baf8bcdf4ba0807623f5879efdca06" target="_blank">Review of recent advances in managing periocular skin malignancies</a></p>
                <p><strong>Paper Venue:</strong> Frontiers in Oncology</p>
                <p><strong>Paper TL;DR:</strong> This article systematically review the latest updates in surgical, radiotherapeutic, and medical management of periocular malignancies.</p>
                <p><strong>Paper Abstract:</strong> Management of cutaneous malignancies can be particularly challenging when they are located in the periocular region. The standard of care for localized disease is complete surgical excision, but this may not be possible without significant disruption to visual structures and facial appearance. Definitive radiation may be an option for some patients who cannot or do not wish to undergo surgery. Advances in systemic treatment options for locally advanced and metastatic skin cancers in the past 10 years have prompted investigation into neoadjuvant treatment of periocular cancers. The use of chemotherapy, immune checkpoint inhibitors, and targeted therapies have all been reported with varying degrees of success. For many patients, targeted therapies or immune checkpoint inhibitors should be considered depending on the cancer type, symptoms, and goals with the input of a multidisciplinary cancer care team. In this article, we systematically review the latest updates in surgical, radiotherapeutic, and medical management of periocular malignancies.</p>
                <p><strong>Cost:</strong> 0.034</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e19.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e19.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN trial (neoadjuvant vs adjuvant ipilimumab + nivolumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized pilot study comparing perioperative (neoadjuvant + adjuvant) ipilimumab+nivolumab versus adjuvant-only ipilimumab+nivolumab in patients with macroscopic stage III resectable melanoma; reported high pathologic response with substantial toxicity and suggested pathologic CR correlates with long-term outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Blank et al., Nat Med 2018</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2018</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Randomized pilot study (Phase 1b/ exploratory randomized)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Arm A: 2 doses ipilimumab 3 mg/kg + nivolumab 1 mg/kg given before surgery and 2 doses after (neoadjuvant + adjuvant) vs Arm B: all 4 doses given after surgery (adjuvant-only).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III disease (clinically detectable nodal disease); resectable</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>20</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Randomized total n=20 (exact per-arm counts not detailed in review)</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab 3 mg/kg + nivolumab 1 mg/kg (neoadjuvant doses described as 2 preoperative doses)</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>2 doses prior to surgery; then 2 doses post-operatively in the neoadjuvant arm</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Postoperative ipilimumab + nivolumab (2 doses in neoadjuvant arm; adjuvant-only arm received 4 doses post-op)</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>All 4 doses of ipilimumab 3 mg/kg + nivolumab 1 mg/kg given after surgery</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Most patients proceeded to surgery; trial was feasible but toxicities were high (some treatment-related toxicity impacted delivery of intended doses). Specific counts of missed surgeries not reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Pathologic complete response (pCR) defined as absence of viable tumor on pathologic review (standard pathologic CR definition used in neoadjuvant melanoma trials).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Pathologic CR 33% in the neoadjuvant arm (as reported in the review).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Overall pathologic response rate 78% (OpACIN reported high pathologic response rate).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Long-term follow-up from OpACIN indicated that pathologic CR reliably correlated with improved relapse-free survival and overall survival (authors reported pCR as a reliable surrogate for outcomes).</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response, toxicity, feasibility; long-term relapse-free survival/overall survival correlations reported in follow-up (RFS/OS association with pCR summarized).</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td>Long-term follow-up referenced; exact median follow-up not provided in review.</td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review cites the trial in support of the concept that neoadjuvant immune exposure elicits robust antitumor immunity and that pathologic response correlates with long-term outcomes; specific mechanistic immune correlates (TCR dynamics, IFN signatures, antigen spreading) are not detailed in the review summary of OpACIN.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors and the review state that neoadjuvant exposure may increase tumor antigen availability to immune effectors and that pathologic responses after neoadjuvant therapy predict RFS/OS (pCR as surrogate).</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>High toxicity in the combination dosing used in OpACIN; review notes high rates of grade ≥3 events in early combination schedules (specific per-trial numbers not fully enumerated in review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td>Some patients had difficulties completing intended postoperative therapy due to toxicity in perioperative schedules; exact rates not reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Toxicity impacted treatment delivery in some patients; specific surgical morbidity/delay rates not detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Small randomized pilot (n=20) with high toxicity using initial dosing; limited power and early exploratory design limit definitive conclusions; potential toxicity-driven bias in feasibility.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>OpACIN (no NCT provided in review)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Review of recent advances in managing periocular skin malignancies', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e19.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>OpACIN-neo trial (dose-optimization neoadjuvant ipilimumab + nivolumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase 2 randomized trial that tested optimized dosing schedules of neoadjuvant ipilimumab + nivolumab in resectable macroscopic stage III melanoma and identified an optimized lower-toxicity schedule with high pathologic CR and overall pathologic response rates.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-nao): a multicentre, phase 2, randomised, controlled trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>OpACIN-neo</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., Lancet Oncol 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase 2, multicenter, randomized dose-optimization trial</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Three randomized arms testing different dosing schedules of neoadjuvant ipilimumab+nivolumab; the optimal arm used ipilimumab 1 mg/kg + nivolumab 3 mg/kg x2 prior to surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable macroscopic stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III disease (clinically detectable nodal disease); resectable</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>86</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Three arms; optimal group n=30 (other arm sizes not specified in review)</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Optimal arm: ipilimumab 1 mg/kg + nivolumab 3 mg/kg given as 2 neoadjuvant doses prior to surgery</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>2 doses prior to surgery (schedule optimized in trial)</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Protocol included perioperative dosing; some arms had adjuvant dosing but review focuses on neoadjuvant optimization (specific adjuvant regimens not detailed).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Only two patients in the optimal arm experienced disease progression prior to planned surgery (one local progression, one distant metastasis); overall feasibility favorable but some progression occurred.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>pCR and major pathologic response metrics used (standard definitions; pCR = 0% viable tumor; MPR typically ≤10% viable tumor as used across neoadjuvant melanoma trials).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Optimal arm pCR 57% (n reported for optimal arm in review).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Overall pathologic response rate in optimal arm 77% (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Review references OpACIN long-term follow-up indicating pathologic CR is a reliable surrogate for relapse-free and overall survival; OpACIN-neo used pathologic response as a key intermediate endpoint.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response rates, radiographic response, progression prior to surgery, safety/toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review does not provide trial-level translational immune correlates for OpACIN-neo; authors used pathologic response as a surrogate and rationale that neoadjuvant exposure augments antitumor immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors and review assert neoadjuvant dosing can induce high pathologic response rates and that pCR after neoadjuvant immunotherapy is associated with improved long-term outcomes; mechanistic immune correlates not detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Toxicity was a major consideration; OpACIN-neo sought to reduce grade ≥3 toxicity relative to earlier schedules; specific overall rates not enumerated in the review but the optimized arm was chosen for better tolerability.</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td>Some patients were unable to proceed with planned adjuvant therapy because of neoadjuvant treatment-related toxicity in trial experience (exact rates not provided).</td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>A small proportion of patients had progression delaying or preventing surgery (2 patients in optimal arm); some patients had surgery delayed or could not undergo surgery in related expansion cohorts.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td>A minority progressed prior to surgery; PRADO expansion later reported some pre-surgical distant metastases (see PRADO entry).</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Although phase 2 randomized, limited sample size per arm; surrogate endpoints (pathologic response) used; longer-term survival data and larger confirmatory trials required.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>OpACIN-neo (no NCT provided in review)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Review of recent advances in managing periocular skin malignancies', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.2">
                <h3 class="extraction-instance">Extracted Data Instance 2 (e19.2)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>PRADO (OpACIN expansion)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>PRADO trial (expansion cohort using OpACIN-neo optimized neoadjuvant schedule)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Expansion cohort using the optimized OpACIN-neo neoadjuvant schedule to evaluate whether high major pathologic response could safely guide less extensive surgery and spare completion lymph node dissection; reported substantial pathologic CR and pathologic response rates and documented some pre-surgical progression and toxicity-related surgical delays.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td></td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>PRADO trial (OpACIN expansion cohort using optimized neoadjuvant schedule)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>PRADO (OpACIN expansion)</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Rozeman et al., expansion cohort (cited in review)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2023</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Expansion cohort following OpACIN-neo (single-arm expansion applied the optimized neoadjuvant schedule)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Single-arm expansion using optimized neoadjuvant ipilimumab 1 mg/kg + nivolumab 3 mg/kg x2 prior to surgery with de-escalation of surgery based on major pathologic response.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage III melanoma (macroscopic nodal disease)</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Macroscopic stage III melanoma; resectable</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>99</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Single-arm expansion n=99</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Ipilimumab 1 mg/kg + nivolumab 3 mg/kg x2 preoperatively (optimized OpACIN-neo schedule)</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>2 doses prior to surgery</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant treatment as per protocol for non-MPR patients; in PRADO, MPR used to guide de-escalation of surgery and adjuvant approach (specific adjuvant regimens not detailed in review).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>In PRADO expansion, 13% of patients experienced progression prior to surgery, 6% of whom had distant metastases prior to surgery; three patients had surgery delayed and one patient could not undergo any surgery due to treatment-related adverse events.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Major pathologic response (MPR) and pathologic CR definitions used (MPR typically defined ≤10% viable tumor; pCR = 0% viable tumor).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Pathologic CR reported as 49% (PRADO expansion cohort per review).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Overall pathologic response rate reported as 72% in PRADO expansion.</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>PRADO used pathologic response as a treatment-guiding surrogate based on OpACIN data that pCR/MPR correlate with RFS/OS; long-term survival data from PRADO not detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic CR, pathologic response, rates of pre-surgical progression, feasibility of surgical de-escalation.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review does not present detailed immune-correlate data from PRADO; PRADO operationalized pathologic response as a treatment-decision biomarker informed by prior OpACIN translational findings.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>PRADO implementation rests on the mechanistic rationale (from OpACIN and neoadjuvant immunotherapy theory) that preoperative immune activation expands effective antitumor T cell clones and that pCR/MPR reflect robust systemic antitumor immunity.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Some patients experienced treatment-related adverse events that precluded surgery (one patient) or delayed surgery; specific grade ≥3 rates not enumerated in the review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td>Some patients were unable to proceed with postoperative therapy due to neoadjuvant toxicity (exact rates not provided).</td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Three patients had surgery delayed and one could not undergo surgery due to treatment-related adverse events in PRADO expansion.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td>Some patients developed distant metastases prior to surgery (6% of progressed patients); further pattern details not provided.</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Single-arm expansion, risk of lead-time or selection bias for de-escalation decisions; limited mature survival data reported in review.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>PRADO (no NCT provided in review)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Review of recent advances in managing periocular skin malignancies', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.3">
                <h3 class="extraction-instance">Extracted Data Instance 3 (e19.3)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>SWOG S1801 (neoadjuvant + adjuvant pembrolizumab vs adjuvant-only pembrolizumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Phase III randomized trial directly comparing neoadjuvant pembrolizumab followed by surgery and adjuvant pembrolizumab versus upfront surgery followed by adjuvant pembrolizumab in resectable stage IIIB–IV melanoma; showed improved event-free survival with the perioperative approach.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>SWOG S1801</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Patel et al., N Engl J Med 2023</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2023</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Phase III randomized trial (direct comparison of perioperative vs adjuvant-only PD-1 therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>True</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Neoadjuvant + adjuvant arm: pembrolizumab given before and after surgery vs Adjuvant-only arm: surgery followed by adjuvant pembrolizumab only.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage IIIB–IV melanoma (advanced resectable disease, primarily patients with clinically detectable nodal disease/ high-risk resected melanoma).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage IIIB–IV melanoma (criteria for resectability as per trial; review summarizes as resectable stage IIIB-IV).</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Neoadjuvant arm n=144 (review reports 144 patients in neoadjuvant group); comparator arm size not reported in review text.</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pembrolizumab given before and after surgery (exact dose/schedule not specified in the review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td>Adjuvant pembrolizumab (duration up to 1 year standard in adjuvant trials; specific duration in SWOG not detailed in review).</td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td>Adjuvant pembrolizumab alone after surgery.</td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Of 144 patients in the neoadjuvant group, 12 patients had disease progression and could not go on to resection; one patient had treatment-related adverse effects that precluded surgery. Several patients were unable to proceed with adjuvant therapy after surgery due to neoadjuvant treatment-related toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>pCR reported (pathologic CR = absence of viable tumor); review reports pathologic CR in neoadjuvant-adjuvant group.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Pathologic CR 21% in the neoadjuvant-adjuvant group (per review).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>The trial reported improved event-free survival for perioperative pembrolizumab; review does not provide a direct trial-level correlation between individual pCR status and survival but notes overall EFS benefit for the neoadjuvant-containing strategy.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Event-free survival (primary reported), pathologic CR, surgical feasibility, safety.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td>At 2 years, EFS was 72% in the neoadjuvant-adjuvant group vs 49% in the adjuvant-only group (absolute difference reported; HR and CI not provided in the review excerpt).</td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td>2-year EFS absolute difference: +23 percentage points (72% vs 49%) in favor of the neoadjuvant-adjuvant arm (reported in review).</td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review does not provide detailed translational immune-correlate data from SWOG S1801; the trial is presented as clinical evidence that perioperative anti-PD-1 improves EFS.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors and the review propose that neoadjuvant therapy enhances exposure of tumor antigens to the immune system leading to broader antitumor T cell responses and improved systemic control; SWOG S1801 provides clinical evidence consistent with this hypothesis.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Several patients in the neoadjuvant arm experienced treatment-related toxicity such that some could not proceed to surgery or adjuvant therapy; exact grade ≥3 rates not provided in the review summary (review notes that neoadjuvant regimens can incur substantial toxicity).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td>Several patients were unable to proceed with adjuvant therapy after surgery because of neoadjuvant treatment-related toxicity (exact rate not specified).</td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>12 patients in the neoadjuvant arm progressed and could not undergo planned resection; one patient had toxicity precluding surgery; additional patients had inability to receive adjuvant therapy post-op due to toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Review provides absolute EFS differences but not HR/CIs; detailed patient-level or subgroup data and translational correlates not reported in the review; neoadjuvant toxicity may limit generalizability.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>SWOG S1801 (trial name provided; no NCT number reported in review)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Review of recent advances in managing periocular skin malignancies', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.4">
                <h3 class="extraction-instance">Extracted Data Instance 4 (e19.4)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Amaria et al.</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Amaria trial (neoadjuvant nivolumab vs neoadjuvant ipilimumab + nivolumab)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>An early exploratory neoadjuvant study in high-risk resectable melanoma comparing single-agent nivolumab to combination ipilimumab+nivolumab which found low single-agent activity leading to early stoppage for nivolumab monotherapy arm and high toxicity in the combination arm.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>Amaria et al. exploratory neoadjuvant trial</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Amaria et al., Nat Med 2018</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2018</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Exploratory randomized neoadjuvant trial (small, early-phase)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Single-agent nivolumab (3 mg/kg up to 4 doses) vs combination ipilimumab 3 mg/kg + nivolumab 1 mg/kg (up to 3 doses) administered preoperatively in resectable stage IIIB-IV melanoma.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage IIIB–IV melanoma (high-risk resectable disease).</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>High-risk resectable stage IIIB–IV melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Nivolumab monotherapy arm: nivolumab 3 mg/kg; combination arm: ipilimumab 3 mg/kg + nivolumab 1 mg/kg (schedules per trial).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>Up to 4 doses nivolumab vs up to 3 doses combination prior to surgery (review summarizes dosing but not precise timing).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Trial was stopped early by DSMB due to significant progression in the nivolumab monotherapy group that prevented surgical resection for some patients; exact numbers not specified in the review excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Imaging/RECIST responses, surgical feasibility, toxicity; trial stopped early due to progression/toxicity concerns.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review does not provide detailed translational immune data from this study; the key translationally relevant finding reported is differential clinical activity and safety between single-agent PD-1 and combination CTLA-4/PD-1 regimens in the neoadjuvant setting.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Authors used the trial to illustrate that single-agent PD-1 may have insufficient preoperative activity in some high-risk resectable patients and that combination therapy yields higher response but at cost of high toxicity; mechanistic immune correlates not detailed in the review.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Combination arm had very high toxicity: review reports 73% of patients in the combination group experienced grade 3 or higher treatment-related adverse events.</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Significant disease progression in nivolumab arm prevented some patients from undergoing planned resection; exact numbers not provided beyond trial stoppage for safety/efficacy concerns.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>This trial provides cautionary evidence that insufficient neoadjuvant single-agent PD-1 therapy can allow progression and loss of resectability; also highlights toxicity trade-offs with combination regimens.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Small exploratory trial stopped early; limits generalizability and provides limited translational data in the review summary.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Review of recent advances in managing periocular skin malignancies', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.5">
                <h3 class="extraction-instance">Extracted Data Instance 5 (e19.5)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NeoCombi</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NeoCombi trial (neoadjuvant dabrafenib + trametinib)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Single-arm phase 2 trial of neoadjuvant BRAF/MEK inhibition (dabrafenib + trametinib for 12 weeks) in BRAFV600-mutant resectable melanoma that produced high pathologic response rates but unexpectedly high recurrence rates on follow-up.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi)</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>NeoCombi</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Long et al., Lancet Oncol 2019</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2019</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Single-arm, open-label, single-center, phase 2 trial (neoadjuvant targeted therapy)</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Single-arm neoadjuvant dabrafenib + trametinib for 12 weeks prior to surgery; adjuvant therapy as per protocol (not detailed in review).</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Patients with resectable stage IIIB–C BRAFV600-mutant melanoma with clinically detectable nodal disease.</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage IIIB–C, BRAF V600-mutant melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td>35</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>Single-arm n=35</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Dabrafenib + trametinib (standard combination dosing; review specifies 12 weeks of therapy prior to surgery).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td>12 weeks of targeted therapy prior to surgery</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>No patients progressed while on neoadjuvant dabrafenib/trametinib (review states none progressed during therapy), and 46% reported improved ease of surgical resection after 12 weeks.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>Pathologic response/pCR definitions used; review reports pathologic response outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Pathologic complete response reported in 49% of patients (17/35 per review summary).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td>Review reports 100% had some pathologic response (i.e., any pathologic response), with 49% pCR.</td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Despite high pCR rates, 57% of patients had recurrence at the time of data cutoff, indicating a disconnect between pathologic response and durable long-term control for neoadjuvant BRAF/MEK in this trial.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic response, surgical ease, recurrence rates on follow-up.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review highlights that targeted neoadjuvant therapy (BRAF/MEK) produced rapid and high pathologic responses but may not induce durable systemic antitumor immunity like immunotherapy; mechanistic correlates not detailed in review.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Review suggests that although BRAF/MEK inhibitors give rapid tumor shrinkage, they may not elicit durable immune memory and thus have higher recurrence despite pCR, contrasting with immunotherapy neoadjuvant results.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Neoadjuvant targeted therapy improved ease of surgical resection in ~46% of patients and was not associated with progression on therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td>High recurrence overall (57% at data cutoff) though patterns (local vs distant) not specified in review.</td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td>NeoCombi provides counterevidence: high pathologic response did not translate into low recurrence rates, challenging the assumption that pCR from any neoadjuvant modality predicts durable benefit.</td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Single-arm, single-center design and limited follow-up at reporting; unexpected high recurrence underscores need for longer follow-up and mechanistic study.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>NeoCombi (no NCT provided in review)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Review of recent advances in managing periocular skin malignancies', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e19.6">
                <h3 class="extraction-instance">Extracted Data Instance 6 (e19.6)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of clinical trials and translational studies in resectable melanoma that compare neoadjuvant-plus-adjuvant immunotherapy with adjuvant-only immunotherapy, or that provide mechanistic evidence for why neoadjuvant exposure improves outcomes. Capture study design, patient population, regimens and timing, surgical feasibility, pathologic response, survival endpoints (HRs and absolute rates), immune correlates (e.g., TCR expansion, TIL infiltration, interferon signatures, antigen spreading), safety, subgroup effects, limitations, and authors' mechanistic claims or counterevidence.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NeoTrio</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>NeoTrio trial (neoadjuvant pembrolizumab +/- sequencing/concurrent with dabrafenib + trametinib)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Randomized trial testing pembrolizumab alone, sequenced with, or given concurrently with dabrafenib + trametinib in resectable BRAF-mutant melanoma to determine optimal combination strategy; early results suggested higher pCR with concurrent therapy but more toxicity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>NeoTriio Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>study_title</strong></td>
                            <td>NeoTriio randomized trial of pembrolizumab alone, sequenced with, or concurrent with dabrafenib + trametinib in resectable BRAF-mutant melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>trial_name_or_id</strong></td>
                            <td>NeoTrio</td>
                        </tr>
                        <tr>
                            <td><strong>citation</strong></td>
                            <td>Long et al., J Clin Oncol 2022 (abstract reported in review)</td>
                        </tr>
                        <tr>
                            <td><strong>year</strong></td>
                            <td>2022</td>
                        </tr>
                        <tr>
                            <td><strong>study_design</strong></td>
                            <td>Randomized trial (multi-arm) comparing neoadjuvant immunotherapy, targeted therapy, and combinations/sequences</td>
                        </tr>
                        <tr>
                            <td><strong>has_direct_comparison</strong></td>
                            <td>False</td>
                        </tr>
                        <tr>
                            <td><strong>arms_description</strong></td>
                            <td>Three-arm randomized: pembrolizumab alone vs pembrolizumab followed by dabrafenib+trametinib (sequence) vs concurrent pembrolizumab + dabrafenib+trametinib.</td>
                        </tr>
                        <tr>
                            <td><strong>patient_population</strong></td>
                            <td>Resectable BRAF-mutant stage III melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>stage_criteria</strong></td>
                            <td>Resectable stage III BRAF V600-mutant melanoma</td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_total</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>sample_size_per_arm</strong></td>
                            <td>In preliminary data, 20 patients treated in the concurrent arm reported in review (other arm sizes not specified).</td>
                        </tr>
                        <tr>
                            <td><strong>intervention_neoadjuvant</strong></td>
                            <td>Pembrolizumab alone or in combination/sequence with dabrafenib + trametinib (exact dosing/schedules not detailed in review).</td>
                        </tr>
                        <tr>
                            <td><strong>neoadjuvant_cycles_and_timing</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intervention_adjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>comparator_adjuvant_only</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>time_to_surgery</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgery_feasibility_missed_surgery</strong></td>
                            <td>Preliminary data: in 20 patients treated with concurrent pembrolizumab + dabrafenib/trametinib, higher pathCR observed vs single modalities but with increased toxicity; longitudinal results not yet available.</td>
                        </tr>
                        <tr>
                            <td><strong>pathologic_response_definition</strong></td>
                            <td>pCR reported as endpoint (exact definitions per trial standards).</td>
                        </tr>
                        <tr>
                            <td><strong>pcr_rate_neoadjuvant</strong></td>
                            <td>Preliminary results for the concurrent arm showed higher pCR than either approach alone (exact % not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>mpr_rate_neoadjuvant</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>association_path_response_with_survival</strong></td>
                            <td>Longitudinal survival data not available at time of review; translational correlates not detailed.</td>
                        </tr>
                        <tr>
                            <td><strong>clinical_endpoints_reported</strong></td>
                            <td>Pathologic CR rates and toxicity in early reporting; longer-term outcomes pending.</td>
                        </tr>
                        <tr>
                            <td><strong>event_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>overall_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>distant_metastasis_free_survival</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>hazard_ratios_and_CIs</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>absolute_benefit_timepoints</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>follow_up_duration_median</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>immune_correlates_summary</strong></td>
                            <td>Review notes higher pCR with concurrent therapy but more toxicity; mechanistic correlates not reported in the review excerpt.</td>
                        </tr>
                        <tr>
                            <td><strong>peripheral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>intratumoral_immune_findings</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>tcr_repertoire_changes</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>antigen_spreading_or_epitope_spreading</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biomarker_predictors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>mechanism_claims_by_authors</strong></td>
                            <td>Implicit mechanistic rationale: combining immunotherapy with targeted therapy may increase immediate tumor regression and possibly augment immune activation, but increased toxicity and unknown durability require further study.</td>
                        </tr>
                        <tr>
                            <td><strong>safety_grade3plus_irAE</strong></td>
                            <td>Concurrent approach associated with more toxicity in preliminary reports (specific rates not provided in review).</td>
                        </tr>
                        <tr>
                            <td><strong>treatment_related_deaths</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>adjuvant_discontinuation_rate</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>surgical_complications_or_delay</strong></td>
                            <td>Longitudinal results pending; preliminary toxicity raised concerns about feasibility for some patients.</td>
                        </tr>
                        <tr>
                            <td><strong>subgroup_analyses</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>recurrence_patterns</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>resistance_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_null_results</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>limitations_and_biases</strong></td>
                            <td>Preliminary abstract-level data with small numbers and limited follow-up; longer-term efficacy and safety unknown.</td>
                        </tr>
                        <tr>
                            <td><strong>funding_and_conflicts</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>trial_registration</strong></td>
                            <td>NeoTrio (no NCT provided in review)</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Review of recent advances in managing periocular skin malignancies', 'publication_date_yy_mm': '2024-03'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma <em>(Rating: 2)</em></li>
                <li>Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <em>(Rating: 2)</em></li>
                <li>Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-nao): a multicentre, phase 2, randomised, controlled trial. <em>(Rating: 2)</em></li>
                <li>PRADO trial (OpACIN expansion cohort) <em>(Rating: 2)</em></li>
                <li>Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. <em>(Rating: 2)</em></li>
                <li>Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. <em>(Rating: 2)</em></li>
                <li>NeoTriio Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>